Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinN (3)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 72
    records per page




    Chagas disease MESHD and SARS-CoV-2 coinfection MESHD does not lead to worse in-hospital outcomes: results from the Brazilian COVID-19 MESHD Registry

    Authors: Israel Molina Romero; Milena Soriano Marcolino; Magda Carvalho Pires; Lucas Emanuel Ferreira Ramos; Rafael Tavares Silva; Milton Henriques Guimaraes Junior; Isaias Jose Ramos de Oliveira; Rafael Lima Rodrigues de Carvalho; Aline Gabrielle Souza Nunes; Ana Lara Rodrigues Monteiro de Barros; Ana Luiza Bahia Alves Scotton; Angelica Aparecida Coelho Madureira; Barbara Lopes Farace; Cintia Alcantara de Carvalho; Fernanda d'Athayde Rodrigues; Fernando Anschau; Fernando Antonio Botoni; Guilherme Fagundes Nascimento; Helena Duani; Henrique Cerqueira Guimaraes; Joice Coutinho de Alvarenga; Leila Beltrami Moreira; Liege Barella Zandona; Luana Fonseca de Almeida; Luana Martins Oliveira; Luciane Kopittke; Luis Cesar de Castro; Luisa Elem Almeida Santos; Maderson Alvares de Souza Cabral; Maria Angelica Pires Ferreira; Natalia da Cunha Severino Sampaio; Neimy Ramos de Oliveira; Saionara Cristina Francisco; Sofia Jarjour Tavares Starling Lopes; Tatiani Oliveira Fereguetti; Veridiana Baldon dos Santos; Victor Eliel Bastos de Carvalho; Yuri Carlotto Ramires; Antonio Luiz Pinho Ribeiro; Freddy Antonio Brito Moscoso; Rogerio Moura; CarIsi Anne Polanczyk; Maria do Carmo Pereira Nunes

    doi:10.1101/2021.03.22.21254078 Date: 2021-03-26 Source: medRxiv

    Objective: Chagas disease MESHD ( CD MESHD) continues to be a major public health burden in Latina America, where co-infection MESHD with SARS-CoV-2 can occur. However, information on the interplay between COVID-19 MESHD and Chagas disease MESHD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD MESHD and COVID-19 MESHD, and to compare it to non- CD MESHD patients. Methods: Patients with COVID-19 MESHD diagnosis were selected from the Brazilian COVID-19 MESHD Registry, a prospective multicenter cohort, from March to September, 2020. CD MESHD diagnosis was based on hospital record at the time of admission. Study data were collected by trained hospital staff using Research Electronic Data Capture (REDCap) tools. Genetic matching for sex, age, hypertension MESHD, DM MESHD and hospital was performed in a 4:1 ratio. Results: Of the 7,018 patients who had confirmed infection with SARS-CoV-2 in the registry, 31 patients with CD MESHD and 124 matched controls were included. Overall, the median age was 72 (64.-80) years-old and 44.5% were male. At baseline, heart failure MESHD (25.8% vs. 9.7%) and atrial fibrillation MESHD (29.0% vs. 5.6%) were more frequent in CD MESHD patients than in the controls (p<0.05 for both). C-reactive protein HGNC levels were lower in CD MESHD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). Seventy-two (46.5%) patients required admission to the intensive care unit. In-hospital management, outcomes and complications were similar between the groups. Conclusions: In this large Brazilian COVID-19 MESHD Registry, CD MESHD patients had a higher prevalence of atrial fibrillation MESHD and chronic heart failure MESHD compared with non- CD MESHD controls, with no differences in-hospital outcomes. The lower C-reactive protein HGNC levels in CD MESHD patients require further investigation.

    A Comprehensive Study on Prediction Reliability of The Severity of Computed Tomography Involvement in Patients with Covid-19 MESHD

    Authors: Semih Kalkan; Volkan Gurler; AHMET Guner; Macit Kalcik; Kamber Kasali; Mustafa Ferhat Keten; Gokhan Tonkaz; Emrah Bayam; Ahmet Karaduman; Mehmet Ozkan

    doi:10.21203/rs.3.rs-278630/v1 Date: 2021-02-26 Source: ResearchSquare

    Purpose: Computed tomography (CT) emerges as a high–sensitivity tool in diagnosing SARS-CoV-2 virus on admission, even with the cases of negative reverse transcription polymerase chain reaction (RT-PCR). Moreover, CT plays a significant role in the evaluation of disease severity. In this study, we aimed to identify several parameters that could aid in evaluating the initial chest CT severity score (CT-SS).Methods: A total of 348 RT-PCR positive patients were divided into three groups by evaluating the chest CT severity score (CT-SS) in detail. These three groups were defined as the CT-SS obtained 0-7, 8-15, 16-40 classified as mild, moderate and severe involvement, respectively. Patients with end-stage malignancy MESHD or immunodeficiency MESHD were excluded from the study. All CT images were evaluated by two chest radiologists, unaware of the clinical data.Results: The analysis of categorical variables show that the chest CT-SS tends to increase with higher CHA2DS2VASC risk score (RS) (p= 0.001), M-CHA2DS2VASC RS (p = 0.001), and CHADS2 RS (p = 0.003). Moreover, age, hypertension MESHD, cardiothoracic ratio, aortic diameter, white blood cell count, neutrophil counts, neutrophil-lymphocyte ratio, c-reactive protein HGNC, D-dimer, ferritin, fibrinogen HGNC, blood urea nitrogen, and lactate dehydrogenase were also found to be associated with higher chest CT-SS. A 5-variable multivariable linear regression model, consisting of more frequently used variables, suggests a higher CHA2DS2VASC RS as the only statistically significant variable predicting a higher severity scoreConclusion: The CHA2DS2VASC RS may assist clinicians in predicting the CT-SS in COVID-19 MESHD patients, even if they are asymptomatic.

    The Prognostic Value of Myocardial Injury MESHD in COVID-19 MESHD Patients and Associated Characteristics

    Authors: jian he; Bicheng Zhang; Quan Zhou; Wenjing Yang; Jing Xu; Tingting Liu; Haijun Zhang; Zhiyong Wu; Dong Li; Qing Zhou; Jie Yan; Cuizhen Zhang; Robert G. Weiss; Guanshu Liu; Zhongzhao Teng; Arlene Sirajuddin; Haiyan Qian; Shihua Zhao; Andrew E. Arai; Minjie Lu; Xiaoyang Zhou

    doi:10.21203/rs.3.rs-251810/v1 Date: 2021-02-17 Source: ResearchSquare

    Background: Since December 2019, Coronavirus disease 2019 MESHD ( COVID-19 MESHD) has emerged as an international pandemic. COVID-19 MESHD patients with myocardial injury MESHD might need special attention. However, understanding on this aspect remains unclear. This study aimed to illustrate clinical characteristics and the prognostic value of myocardial injury MESHD to COVID-19 MESHD patients. Methods: This retrospective, single-center study finally included 304 hospitalized COVID-19 MESHD cases confirmed by real-time RT-PCR from January 11 to March 25, 2020. Myocardial injury MESHD was determined by serum high-sensitivity troponin I (Hs-TnI). The primary endpoint was COVID-19 MESHD associated mortality. Results: Of 304 COVID-19 MESHD patients (median age, 65 years; 52.6% males), 88 patients (27.3%) died (61 patients with myocardial injury MESHD, 27 patients without myocardial injury MESHD on admission). COVID-19 MESHD patients with myocardial injury MESHD had more comorbidities ( hypertension MESHD, chronic obstructive pulmonary disease MESHD, cardiovascular disease MESHD, and cerebrovascular disease MESHD); lower lymphocyte counts, higher C-reactive protein HGNC ( CRP HGNC, median, 84.9 vs 28.5 mg/L, p<0.001), procalcitonin levels (median, 0.29 vs 0.06 ng/ml, p<0.001), inflammatory and immune response markers; more frequent need for noninvasive ventilation, invasive mechanical ventilation; and was associated with higher mortality incidence (hazard ratio, HR=7.02, 95% confidence interval, CI, 4.45-11.08, p<0.001) than those without myocardial injury MESHD. Myocardial injury MESHD (HR=4.55, 95% CI, 2.49-8.31, p<0.001), senior age, CRP HGNC levels, and novel coronavirus pneumonia MESHD ( NCP PROTEIN) types on admission were independent predictors to mortality in COVID-19 MESHD patients. Conclusions: COVID patients with myocardial injury MESHD on admission is associated with more severe clinical presentation and biomarkers. Myocardial injury MESHD and higher HsTNI are both strongest independent predictors to COVID related mortality after adjusting confounding factors. In addition, senior age, CRP HGNC levels and NCP PROTEIN types are also associated with mortality. Trial registration: Not applicable.

    Outcomes of COVID-19 MESHD among Patients with End Stage Renal Disease MESHD on Remdesivir

    Authors: Vijairam Selvaraj; Muhammad Baig; Kwame Dapaah-Afriyie; Arkadiy Finn; Atin Jindal; George Bayliss

    doi:10.1101/2021.02.10.21251527 Date: 2021-02-15 Source: medRxiv

    BACKGROUNDSince the beginning of the COVID-19 pandemic MESHD, there has been widespread use of remdesivir in adults and children. There is little known information about its outcomes in patients with severe renal dysfunction MESHD or end-stage renal disease MESHD who are on hemodialysis. METHODSA retrospective, multicenter study was conducted on patients with end-stage renal disease MESHD on hemodialysis that were discharged after treatment for COVID-19 MESHD between April 1st and December 31st, 2020. Primary endpoints were the length of stay, mortality, maximum oxygen requirements along with the escalation of care needing mechanical ventilation. Secondary endpoints included change in C reactive protein HGNC, d dimer levels, and disposition. RESULTSA total of 52 charts were reviewed, of which 28 met the inclusion criteria. 14 patients received remdesivir, and 14 patients did not receive remdesivir. The majority of patients were caucasian, female, with diabetes mellitus MESHD and hypertension MESHD. The mean age was 65.33 +14.14 years. All the patients in the remdesivir group received dexamethasone as compared to only 30% of patients in the non-remdesivir group. There was no significant difference in C reactive protein HGNC, d dimer levels, and disposition between the two groups. Approximately 35% of the patients died, 18% required intensive ventilation, and the mean length of stay was 12.21 days. DISCUSSIONThe study demonstrated no clinically significant difference in length of stay, maximum oxygen requirements, or mortality in COVID-19 MESHD patients with end-stage renal disease MESHD in the remdesivir group as compared to the non-remdesivir group. Further studies are needed to study the effects of remdesivir on the renal function and disease course in patients with chronic kidney disease MESHD stage 4 or 5 that are not on dialysis.

    The Age Again in The Eye of The Covid-19 MESHD Storm: Evidence-Based Decision Making.

    Authors: M. Carmen Martín; Aurora Jurado; Cristina Abad-Molina; Antonio Orduña; Oscar Yarce; Ana M. Navas; Vanesa Cunill; Danilo Escobar; Francisco Boix; Sergio Burillo-Sanz; María C. Vegas-Sánchez; Yesenia Jiménez-de las Pozas; Josefa Melero; Marta Aguilar; Oana Irina Sobieschi; Marcos López-Hoyos; Gonzalo Ocejo-Vinyals; David San Segundo; Delia Almeida; Silvia Medina; Luis Fernández-Pereira; Esther Vergara; Bibiana Quirant; Eva Martínez-Cáceres; Marc Boigues; Marta Alonso; Laura Esparcia-Pinedo; Celia López-Sanz; Javier Muñoz-Vico; Serafín López-Palmero; Antonio Trujillo; Paula Álvarez; Álvaro Prada; David Monzón; Jesús Ontañón; Francisco M. Marco; Sergio Mora; Ricardo Rojo; Gema González-Martínez; María T. Martínez-Saavedra; Juana Gil-Herrera; Sergi Cantenys-Molina; Manuel Hernández; Janire Perurena-Prieto; Beatriz Rodríguez-Bayona; Alba Martínez; Esther Ocaña; Juan Molina

    doi:10.21203/rs.3.rs-228480/v1 Date: 2021-02-10 Source: ResearchSquare

    Background: One hundred million of contagions, more than 2 million deaths and less than one year of COVID-19 MESHD have changed our lives and our health management systems forever. Ageing is known to be one of the significant determinants for COVID-19 MESHD severity. Two main reasons underlie this: immunosenescence and age correlation with main COVID-19 MESHD comorbidities such as hypertension or dyslipidaemia MESHD. This study has two aims. The first is to obtain cut-off points for laboratory parameters that can help us in clinical decision-making. The second one is to analyse the effect of pandemic lockdown on epidemiological, clinical, and laboratory parameters concerning the severity of the COVID-19 MESHD. For these purposes, 257 of SARSCoV2 inpatients during pandemic confinement were included in this study. Moreover, 584 case records from a previously analysed series, were compared with the present study data. Results: Concerning the characteristics of lockdown series, mild cases accounted for 14.4%, 54.1% were moderate and 31.5%, severe. There were 32.5% of home contagions, 26.3% community transmissions, 22.5% nursing home contagions, and 8.8% corresponding to frontline worker contagions regarding epidemiological features. Age >60 and male sex are hereby confirmed as severity determinants. Equally, higher severity was significantly associated with higher IL6 HGNC, CRP HGNC, ferritin, LDH, and leukocyte counts, and a lower percentage of lymphocyte, CD4 HGNC and CD8 HGNC count. Comparing this cohort with a previous 584-cases series, mild cases were less than those analysed in the first moment of the pandemic and dyslipidaemia became more frequent than before. Age, lymphocyte count and LDH had similar distributions at both moments. IL-6 HGNC, CRP HGNC and LDH values above 69 pg/mL, 97 mg/L and 328 U/L respectively, as well as a CD4 HGNC T-cell count below 535 cells/μL, were the best cut-offs predicting severity since these parameters offered reliable areas under the curve. Conclusion: Age, sex and dyslipidaemia together with selected laboratory parameters on admission can help us predict COVID-19 MESHD severity and, therefore, make clinical and resource management decisions. Demographic features associated with lockdown could affect the homogeneity of the data and the robustness of the results.

    Clinical Presentation, Management and Outcome of Staffs with COVID-19 Disease MESHD: a large tertiary Oil and Refinery Grand Hospital Study

    Authors: Bahram Dehghan; Ahmad abeshtan; Abdullah Sarami; Saied Saeidimehr; Elham Maraghi; Fakher Rahim

    doi:10.21203/rs.3.rs-218397/v1 Date: 2021-02-07 Source: ResearchSquare

    Objective The aim of the present study was to assess clinical characteristics, managing and controlling, and in-hospital outcome of COVID-19 MESHD among oil refinery workers in a single referral center.Methods This cross-sectional study was conducted in a non-COVID single referral center from March to August 2020. At the Naft grand Hospital, the COVID-19 MESHD specimen collection and molecular detection unit was established with staff trained to collect suitable samples (sufficiently deep swabs), storage, packaging, and transportation. The diagnosis of COVID-19 infection MESHD (SARS-CoV-2) was confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay.Results Overall, 500 patients with confirmed COVID-19 MESHD infection were included, of which the most common comorbidities were hypertension MESHD (52.2%) and diabetes MESHD (45.6%). Moreover, 298 patients (59.6%) had one to three comorbidities, 148 patients (29.6%) had four to six cases, and two patients (0.4%) had seven and more comorbidities. Finally, 23 people (4.6%) have cancer MESHD and 206 people (41.2%) have other diseases. 390 (78.8%) received Kaletra, and 387 (78.02%) receive Azithromycin. Overall, PCR test result was positive in 377 (75.4%) patients, computed tomography scan (CT-scan) test was positive in 413 (82.6%) patients, and CRP HGNC test had positive result in 335 patients (67%) patients.Conclusion Most referred cases were survivors with mild to moderate symptoms, and a few of them were unfortunately non-survivor. This could be due to those people with mild COVID-19 MESHD symptoms may respond well to the treatment and institutional isolation. Thus, good and evidence-based clinical care combined with strong public health interventions will save the lives of thousands, if not millions, worldwide.

    COVID-19 MESHD anosmia MESHD and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 MESHD (Health Outcome Predictive Evaluation for COVID-19 MESHD) Registry

    Authors: Jesús Porta-Etessam; Iván Núñez-Gil; Nuria González García; Cristina Fernández; María Viana-LLamas; Charbel Maroun Eid; Rodolfo Romero; Marta Molina; Aitor Uribarri; Victor Becerra; Marcos García Aguado; Jia Huang; Elisa Rondano; Enrico Cerrato; Emilio Alfonso; Alex Castro; francisco Marín; Sergio Raposeiras; Martino Pepe; Gisela Feites; Paloma Mate; Bernardo Cortese; Luís Buzón; Jorge Javita; Vicente Estrada

    doi:10.21203/rs.3.rs-158894/v1 Date: 2021-01-27 Source: ResearchSquare

    Olfactory and gustatory dysfunctions MESHD ( OGD MESHD) are a frequent symptom of Coronavirus disease 2019 MESHD ( COVID-19 MESHD). It has been proposed that the neuroinvasive potential of the novel SARS-CoV-2 could be due to olfactory bulb invasion, conversely studies suggest it could be a good prognostic factor. The aim of the current study was to investigate the prognosis value of OGD in COVID-19 MESHD.These symptoms were recorded on admission from a cohort study of 5868 patients with confirmed or highly suspected COVID-19 MESHD infection included in the multicenter international HOPE Registry (NCT04334291).There was statistical relation in multivariate analysis for OGD in gender, more frequent in female 12.41% vs 8.67% in male, related to age, more frequent under 65 years, presence of hypertension MESHD, dyslipidemia MESHD, diabetes MESHD, smoke, renal insufficiency MESHD, lung, heart, cancer MESHD and neurological disease MESHD. We did not find statistical differences in pregnant (p=0.505), patient suffering cognitive (p=0.484), liver (p=0.1) or immune disease (p=0.32). There was inverse relation (protective) between OGD MESHD and prone positioning (0.005) and death MESHD (<0.0001), but no with ICU (0.165) or mechanical ventilation (0.292). On univariable logistic regression OGD was found to be inversely related to death in COVID-19 MESHD patients. The Odds Ratio was 0.26 (0.15-0.44) (p<0.001) and Z was -5.05.The presence of anosmia MESHD is fundamental in the diagnosis of SARS.CoV-2 infection MESHD, but also could be important when classifying patients and in therapeutic decisions. Even more knowing that it is an early symptom of the disease. Knowing that other situations as being Afro-American or Latino-American, Hypertension MESHD, renal insufficiency MESHD, or increase of C-reactive protein HGNC ( CRP HGNC) imply a worse prognosis we can make a clinical score to estimate the vital prognosis of the patient.The exact pathogenesis of SARS-CoV-2 that causes olfactory and gustative disorders remains unknown but seems related to the prognosis. This point is fundamental, insomuch as could be a plausible way to find a treatment. 

    Evaluation of Patients With Covid-19 MESHD Diagnosis for Chronic Diseases MESHD

    Authors: Murat Altuntas; Habip Yilmaz; Emre Güner

    doi:10.21203/rs.3.rs-135761/v1 Date: 2020-12-24 Source: ResearchSquare

    Aim: Covid-19 MESHD is one of the most important pandemics in the world history. Chronic diseases MESHD, which are risk factors that increase the case fatality rates, have been the leading cause of death MESHD all over the world. In this study, it was aimed to detect coexisting diseases in patients hospitalized with the diagnosis of Covid-19 MESHD.           Material and Method: It was carried out with the data of 229 inpatients in an intensive care unit between 01.06.2020 - 30.06.2020. Among the inclusion criteria of the study; it is necessary to have a diagnosis confirmed by PCR test, to be hospitalized in the relevant intensive care unit on the date of the study and to have data accessible through the hospital automation system. According to literature; chronic diseases of the patients and their effects on the covid-19 MESHD process were evaluated. Statistical analyzes were performed using the Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp .; Armonk, NY, USA).Results: It was seen that the average age of the patients were 61.4±15.9 years old. While the average symptom duration was 8.2±5.3 days; total hospitalization period was 13.1±5.9 days. The length of stay of 75 patients who were sent to intensive care unit was determined as 10.1±7.1. The most common chronic disease MESHD among patients was hypertension MESHD with 47.2%. This was followed by diabetes mellitus MESHD (32.8%) and heart disease MESHD (27.5%), respectively. In the presented study, cough MESHD (59.4%), fever MESHD (58.5%) and shortness of breath MESHD (45.9%) were found to be the most common symptoms. Leukopenia MESHD, impairments in liver and muscle enzymes, abnormal C-reactive protein HGNC, ferritin and d-dimer levels were the important laboratory findings.Conclusion: Particular attention should be paid to the elderly Covid-19 MESHD patients with chronic diseases MESHD, especially DM MESHD, HT MESHD and cancer MESHD.

    Results of Favipiravir Combined Treatment in Intensive Care Patients With Covid-19 MESHD

    Authors: Habip Yilmaz; Emre Güner; Murat Altuntas

    doi:10.21203/rs.3.rs-132216/v1 Date: 2020-12-19 Source: ResearchSquare

    Aim: Covid-19 MESHD ( Coronavirus disease 2019 MESHD) is a disease that has already taken place in human history. Although there is still no effective treatment and vaccine protocol, different treatment options are being tried. In this study, it was aimed to determine the basic characteristics and changes in laboratory findings of patients who were hospitalized with the diagnosis of Covid-19 MESHD in the intensive care unit and underwent treatment protocol containing favipiravir.Material and Method: It was carried out with the data of 179 inpatients in an intensive care unit between 01.06.2020 - 30.06.2020. The inclusion criterias of the study are to have a diagnosis of COVID-19 MESHD confirmed by PCR test, to be hospitalized in the intensive care unit, receiving therapy combined with favipravir and to have access to its data through the automation system. According to literature; the sociodemographic characteristics, some basic characteristics and some laboratory findings of the patients were evaluated. Statistical analyzes were performed using the Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp .; Armonk, NY, USA).Findings: The average age of the study group is 60.9±16.4 years and 65.9% (n:118) of them are male. According to the clinical classification, more than half (50.8%, n: 91) are included in the "high" clinical classification. The most common chronic disease MESHD is " hypertension MESHD ( HT MESHD)" (42.5%, n:76) and the most common symptom is " fever MESHD" (57.5%, n: 103). While 82.7% (n: 148) have widespread CT (Computed tomography) findings, CPR HGNC ( C-Reactive protein HGNC) positivity rate is 65.4% (n: 117). Statistical significant difference was detected between three measurements of blood urea nitrogen (BUN), aspartat aminotransferase ( AST HGNC), alanin aminotransfrase (ALT), CRP HGNC between the 1st and the 3rd day. Conclusion: Favipiravir demonstrates a proper safety profile. However, its side effects teratogenicity, hyperuricaemia and QTc MESHD (corrected QT interval) prolongation have not yet been adequately studied. It may be safe and tolerable in short-term use, but more evidence is needed to assess the longer-term effects of treatment.

    Intubation prognosis in COVID-19 MESHD patients and associated factors: a cross-sectional study

    Authors: Mostafa Mohammadi; Hesam Aldin Varpaei; Majid Amini

    doi:10.21203/rs.3.rs-115894/v1 Date: 2020-11-25 Source: ResearchSquare

    Background: In December 2019, a new pathogen, HCoV, or New Corona Virus 2019 (2019-nCoV), was recognized in Wuhan, China, causing a pandemic. COVID-19 MESHD has a wide range of clinical severity. Approximately 3.2% of patients within some periods of the disease require intubation and invasive ventilation. Methods: This study was descriptive-analytical and was conducted in the Imam Khomeini Hospital. Patients with Covid-19 MESHD who required endotracheal intubation were identified and their clinical signs and laboratory parameters were recorded. SPSS23 software was used for statistical analysis. Results: 120 patients with coronavirus with different conditions were evaluated. The mean age was 55±14. 30 patients had cardiovascular disease MESHD ( hypertension MESHD) and 20 endocrine disease MESHD( diabetes MESHD). Respiratory acidosis MESHD, decreased oxygen saturation, lymphopenia MESHD, and increased CRP HGNC were the most common finding before intubation. 31 patients had no comorbidity conditions. However, 27 patients had more than one comorbidity condition, and 23 experienced acute respiratory distress syndrome MESHD. The mortality rate was 49.2%. Discussion: Although all laboratory parameters and patients symptoms can affect the treatment outcome, it was found that WBC and absolute lymphocyte count, BUN, SOFA and APACHE scores, inflammatory index ratio CRP HGNC / LDH % CRP HGNC / ESR% and ESR / LDH%, arterial blood gas indices, pulse rate, and patient temperature before intubation are among the parameters that can affect the patient's 14-day prognosis. Conclusion: Except for the mentioned items, CRP HGNC / LDH% ratio seems to be a good indicator for checking the prognosis of discharge or death MESHD of patients within 14 days, However, CRP HGNC / ESR% and ESR / LDH% are appropriate criteria for determining the prognosis for discharge or stay in the ICU for more than 14 days.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.